Compare Wheaton Precious Metals Corp (WPM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wheaton Precious Metals Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Wheaton Precious Metals Corp trades at $138.65 (market cap $61.17B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Wheaton Precious Metals Corp is far larger — about 6.1× State Street SPDR S&P Biotech ETF's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wheaton Precious Metals Corp for 66 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| WPM | XBI | |
|---|---|---|
Market Cap | $61.17B | $10.11B |
Volume | 1,092,361 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $165.72 | $169.55 |
52-Week Low | $94.37 | $104.99 |
Typical Hold Time | 66 Days | 38 Days |
Enterprise Value | $63.05B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wheaton Precious Metals (WPM) trades at $134.96, up 0.95% on the day, with a bearish technical signal but strong fundamentals. The company reported record H1 2026 revenues and has beaten earnings estimates for three consecutive quarters. Management targets 50% production growth by 2030 without new capital, supported by a robust pipeline of streaming deals. Cash flow from operations surged to $1.9 billion in 2025, though 2026 projections show significant investing outflows.
The outlook is supported by analyst consensus with an 80% buy rating and a $164.80 price target, implying 22% upside. Key risks include execution of growth targets, gold price volatility, and high valuation multiples. The stock offers exposure to precious metals with a capital-light model, but investors face near-term technical headwinds amid broader market sentiment shifts.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
